Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

19.49 +0.29 (+1.51%)
Streaming Delayed Price Updated: 12:39 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
Earnings Scheduled For November 10, 2022
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. 
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Recap: UroGen Pharma Q4 Earnings
UroGen Pharma (NASDAQ:URGN) reported its Q4 earnings results on Monday, March 21, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
From UroGen Pharma Ltd.
Via Business Wire
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
From UroGen Pharma Ltd.
Via Business Wire
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday. 
Via Benzinga
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session
Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday. 
Via Benzinga
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Upcoming 2022 Conferences
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows. 
Via Benzinga
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
On Monday, 198 companies reached new 52-week lows. 
Via Benzinga
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
From UroGen Pharma Ltd.
Via Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
Earnings Outlook For UroGen Pharma
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that UroGen Pharma... 
Via Benzinga
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
From UroGen Pharma Ltd.
Via Business Wire
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
UroGen Pharma's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q4, UroGen Pharma's (NASDAQ:URGN) reported sales totaled $16.17 million. Despite a 5.82% increase in earnings, the company posted a... 
Via Benzinga
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback